使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Brent Turner - President
Brent Turner - President
Good morning. I'm Brent Turner, President of Acadia Healthcare, and I'd like to welcome you to our third quarter 2016 conference call. To the extent any non-GAAP financial measure is discussed in today's call, you'll also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP on our website by viewing yesterday's news release under the Investors link.
各位早安。我是 Acadia Healthcare 總裁 Brent Turner,歡迎各位參加我們 2016 年第三季電話法說會。若今日電話會議中討論任何非 GAAP 財務衡量指標,您亦可在我們網站的 Investors 連結下,查看昨日新聞稿,以取得該衡量指標與依 GAAP 計算之最直接可比財務衡量指標的調節表。
This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2016 and beyond. For this purpose, any statements made during this call that are not statements of historical fact may be deemed to be forward-looking statements.
本次電話會議可能包含《1995 年私人證券訴訟改革法案》所定義之前瞻性陳述,包括但不限於關於 Acadia 對 2016 年及其後各季與全年預期財務表現的陳述。就此而言,本次電話會議中任何非歷史事實之陳述,均可能被視為前瞻性陳述。
Without limiting the foregoing, the words believes, anticipates, plans, expects, and similar expressions are intended to identify forward-looking statements. You are hereby cautioned that these statements may be affected by the important factors, among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's third quarter news release, and consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. The company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
在不限制前述內容之前提下,「相信」、「預期」、「計畫」、「期望」及類似用語旨在辨識前瞻性陳述。謹此提醒您,這些陳述可能受到多項重要因素影響(包括但不限於 Acadia 向美國證券交易委員會提交之文件及公司第三季新聞稿中所載因素),因此實際營運與結果可能與前瞻性陳述所討論之結果存在重大差異。除非因新資訊、未來事件或其他原因,公司不承擔公開更新任何前瞻性陳述之義務。
At this time, for opening remarks, I'll now turn the conference over to our Chairman and Chief Executive Officer, Joey Jacobs.
現在進入開場致詞,我將把會議交給我們的董事長兼執行長 Joey Jacobs。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Good morning, and welcome to our third quarter conference call. In addition to Brent, I'm here today with our Chief Financial Officer, David Duckworth, and other members of our executive management team. David and I each have some remarks about the third quarter and our outlook for Acadia. Then we'll open the line for your questions.
各位早安,歡迎參加我們第三季電話法說會。除了 Brent 之外,今天與會的還有我們的財務長 David Duckworth,以及其他執行管理團隊成員。David 與我將分別就第三季表現與 Acadia 的展望發表一些看法,之後我們將開放提問。
David is going to take us through the specific numbers this morning, so let me go right to the topic of most interest -- our adjusted earnings per diluted share of $0.58 for the third quarter. As we indicated in our pre-release, we've identified three primary reasons why these earnings did not meet our expectations. The first is lower same-facility revenue in our UK operations, which was 5.1% for the third quarter, compared with 8.5% for the third quarter last year and 6.7% for the second quarter of 2016.
David 今天早上會帶大家檢視具體數字,因此我先直接談大家最關心的主題——第三季稀釋後每股調整後盈餘為 0.58 美元。如同我們在預先發布中所指出,我們已辨識出三項主要原因,說明為何該盈餘未達我們的預期。第一項是我們英國業務的同店營收較低,第三季為 5.1%,相較去年第三季為 8.5%,以及 2016 年第二季為 6.7%。
We believe the third quarter was a period of distraction and concern for all our UK staff. Two weeks into the third quarter and three weeks after the surprising Brexit vote, the CMA announced that it was referring their Priory acquisition to a Phase II investigation, setting off an intensive internal wave of meetings, analyses and planning that required the involvement from our UK corporate staff and put significant pressure on the senior management of many of our UK facilities. This pressure did not subside throughout the quarter and even continues today.
我們認為第三季對所有英國員工而言是一段分心且憂慮的期間。第三季開始兩週、且在令人意外的英國脫歐公投結果後三週,英國競爭與市場管理局(CMA)宣布將我們對 Priory 的收購案移送第二階段(Phase II)調查,隨即引發密集的內部會議、分析與規劃浪潮,需要英國總部人員投入,並對多家英國機構的高階管理層造成顯著壓力。這種壓力在整個季度都未緩解,甚至至今仍在持續。
In our work to understand the third quarter, we have not discovered anything that offers a more compelling explanation for the same-facility results. Although we note that the 8.5% same-facility revenue growth for the third quarter last year represented a tough comparison, we believe the UK same-facility performance should improve once the divestiture transaction closes. In that regard, we are pleased to announce our definitive agreement to sell 21 existing UK facilities and one de novo facility and fulfillment of our undertakings to the CMA. Should the CMA approve the transaction, which we fully expect to happen, we will immediately begin to integrate Priory's operation as soon as the sale is complete.
在我們釐清第三季情況的過程中,並未發現任何更具說服力的解釋來說明同店表現。雖然我們注意到去年第三季 8.5% 的同店營收成長形成了較高的比較基期,但我們相信,一旦資產剝離交易完成,英國同店表現應可改善。就此,我們很高興宣布已簽署具約束力的最終協議,將出售 21 家既有英國機構及 1 家新設(de novo)機構,以履行我們對 CMA 的承諾。若 CMA 核准該交易(我們完全預期將會核准),在出售完成後,我們將立即開始整合 Priory 的營運。
We continue to target cost efficiencies for this transaction of $20 million and we continue to believe that Priory represents an outstanding growth opportunity for Acadia. Proceeds from the sale are approximately $390 million in cash and we expect to be able to redeploy those proceeds relatively quickly into investments and new acquisitions in the US.
我們仍以本交易可帶來 2,000 萬美元的成本效率為目標,並持續相信 Priory 對 Acadia 而言是極佳的成長機會。出售所得約為 3.90 億美元現金,我們預期能相對迅速地將該等資金重新配置至美國的投資與新併購案。
The second factor was same-facility revenue growth in the US of 6.5%, which increased compared to 5.9% for the third quarter last year, but which was below our expectations for the quarter. The softness in our same-facility volumes in the third quarter was affected by a handful of our facilities and was not the result of any material labor shortages. While we have a few markets that have labor challenges, this is not materially affecting our growth rate. In the US, through the nine months of 2016, we've recruited 125 psychiatrists to our facilities, which is similar to the total number recruited for all of 2015. These numbers clearly demonstrate that Acadia has the ability to recruit psychiatrists where needed. Thus far in the fourth quarter, US same-facility patient days grew 6.7% in October, 50 basis points better than our experience for the third quarter.
第二項因素是美國同店營收成長為 6.5%,雖較去年第三季的 5.9% 提升,但仍低於我們對本季的預期。第三季同店量能偏弱主要受少數機構影響,並非任何重大人力短缺所致。雖然我們在少數市場確實面臨人力挑戰,但並未對我們的成長率造成重大影響。在美國,2016 年前九個月我們已為旗下機構招募 125 名精神科醫師,與 2015 年全年招募總數相近。這些數據清楚顯示 Acadia 具備在需要之處招募精神科醫師的能力。截至第四季目前為止,美國同店病患日(patient days)在 10 月成長 6.7%,較第三季經驗高出 50 個基點。
The third factor to affect revenues for the third quarter concerns several of the de novo facilities open since the start of 2015, which have not ramped their occupancy and revenue as quickly as we expected. We have four de novo facilities at various phases of ramp up. While each one has had unique challenges, we now have a better understanding and plan through these issues going forward for future openings. We do not have any new de novo facilities coming on line until the third quarter of 2017. The census at the existing de novos are ramping nicely.
第三項影響第三季營收的因素,與自 2015 年初以來開設的數家新設(de novo)機構有關,其入住率與營收爬坡速度未如我們預期。我們目前有四家新設機構處於不同的爬坡階段。雖然每一家都面臨其獨特挑戰,但我們如今對這些問題有了更好的理解,並已制定因應計畫,以利未來新開設案的推進。我們在 2017 年第三季之前不會有任何新的新設機構上線。現有新設機構的住院人數(census)正穩健提升。
Despite these challenges, we remain confident of our ability to generate sustained profitable growth. We are a clear leader in each of our service lines. Industry demand is growing due to strong demographics and increasing access and parity, while capacity remains constrained. We have demonstrated our ability to add beds to the existing facilities at scale across our operations. These include 688 beds added through the first nine months of 2016, 548 to existing facilities, and 140 beds through two de novo facilities through, which we leverage local supply imbalances to better serve our communities and drive same-facility revenues.
儘管面臨這些挑戰,我們仍對持續創造具獲利性的成長能力充滿信心。我們在各項服務線中皆為明確的領導者。由於人口結構趨勢強勁、可近性提升與同等給付(parity)推進,產業需求正在成長,而供給量能仍受限制。我們已證明能在整體營運中以規模化方式為既有機構增設床位。這包括 2016 年前九個月新增 688 床,其中 548 床來自既有機構,另有 140 床來自兩家新設(de novo)機構;我們藉由利用在地供需失衡,更好地服務社區並帶動同店營收。
Our pipeline of potential acquisitions and joint venture transactions remains robust and we have tremendous experience in integrating and enhancing acquired facilities. In closing, we remain confident, excited and optimistic about our prospects for our continued growth and our ability to drive long-term shareholder value.
我們潛在併購與合資交易的案源管線仍然強勁,我們在整合並提升所收購機構方面也具備豐富經驗。最後,我們對持續成長的前景以及推動長期股東價值的能力,仍然充滿信心、期待且樂觀。
Thanks for your time this morning and interest in Acadia. Now, here is David to discuss the financials in more detail.
感謝各位今天早上的時間以及對 Acadia 的關注。接下來請 David 更詳細說明財務表現。
David Duckworth - CFO
David Duckworth - CFO
Thanks, Joey, and good morning. Acadia's revenue for the third quarter of 2016 increased 53.1% to $734.7 million from $479.7 million for the third quarter of 2015. Adjusted income from continuing operations attributable to Acadia's stockholders was $49.9 million, up 13.7% from $43.9 million. Adjusted EPS for the third quarter of 2016 was $0.58, down 6.5% from $0.62 for the third quarter of 2015. For the third quarter, we have provided constant currency financial information in our press release, which assumes the current period exchange rate is equal to the prior period exchange rate to present our financial results without the effect of the currency fluctuations.
謝謝你,Joey,各位早安。Acadia 2016 年第三季營收較 2015 年第三季的 4.797 億美元成長 53.1%,至 7.347 億美元。歸屬於 Acadia 股東之持續營運調整後淨利為 4,990 萬美元,較 4,390 萬美元成長 13.7%。2016 年第三季調整後每股盈餘(EPS)為 0.58 美元,較 2015 年第三季的 0.62 美元下降 6.5%。就第三季而言,我們在新聞稿中提供了固定匯率(constant currency)財務資訊,假設本期匯率等同於前期匯率,以在不受匯率波動影響下呈現我們的財務結果。
For the third quarter of 2016, adjusted EPS on a constant currency basis was $0.67, which is an increase of 8.1%. For the third quarter of 2016, our adjusted EPS excludes a loss on divestiture of $174.7 million, debt extinguishment costs of $3.4 million, and transactional-related expenses of $1.1 million. For the third quarter of 2015, adjusted EPS excludes debt extinguishment costs of $10 million, transaction-related expenses of $5.8 million and a loss on foreign currency derivatives of $1 million.
2016 年第三季,以固定匯率計算之調整後 EPS 為 0.67 美元,成長 8.1%。2016 年第三季,我們的調整後 EPS 排除:資產剝離損失 1.747 億美元、債務清償成本 340 萬美元,以及交易相關費用 110 萬美元。2015 年第三季,調整後 EPS 排除:債務清償成本 1,000 萬美元、交易相關費用 580 萬美元,以及外匯衍生性金融商品損失 100 萬美元。
Weighted average diluted shares outstanding increased 22% for the comparable quarters, primarily due to the equity that we issued in January and February of 2016 related to the acquisition of Priory.
可比季度的加權平均稀釋在外流通股數增加 22%,主要係因我們於 2016 年 1 月與 2 月為收購 Priory 而發行的股權所致。
Acadia's tax rate on adjusted income from continuing operations before income taxes was 21.8% for the third quarter of 2016, compared with 25.6% for the third quarter last year. For the third quarter of 2016, Acadia's same-facility revenue increased 6.2% from the third quarter of 2015, with a 7.3% increase in patient days, while revenue per patient day was flat with the same prior year quarter. Same-facility EBITDA margin was 26.9% for the latest quarter versus 27.4% for the third quarter of 2015.
Acadia 以所得稅前之持續營運調整後淨利計算之稅率,2016 年第三季為 21.8%,相較去年第三季為 25.6%。2016 年第三季,Acadia 同店營收較 2015 年第三季成長 6.2%,其中病患日(patient days)增加 7.3%,而每病患日營收與去年同期持平。同店 EBITDA 利潤率於最新季度為 26.9%,相較 2015 年第三季為 27.4%。
Consolidated adjusted EBITDA increased 43.7% to $155.8 million, which was 21.2% of consolidated revenue compared with $108.5 million, or 22.6% of consolidated revenue for the third quarter of 2015. Our operating cash flow increased 42.7% to $79.4 million for the third quarter from $53 million for the third quarter of 2015.
合併調整後 EBITDA 增加 43.7% 至 1.558 億美元,占合併營收的 21.2%,相較於 2015 年第三季的 1.085 億美元(占合併營收的 22.6%)。我們第三季的營運現金流較 2015 年第三季的 5,300 萬美元增加 42.7% 至 7,940 萬美元。
Turning to guidance -- as announced in this morning's news release, we have revised our 2016 guidance for adjusted earnings per diluted share to a range of $2.41 to $2.42. This adjustment is primarily a result of the lower than expected adjusted EPS for the third quarter, the decline in the US dollar to British pound sterling exchange rate, and the impact of the divestiture transaction.
接著談指引——如同今早新聞稿所宣布,我們已將 2016 年稀釋後每股調整後盈餘(adjusted earnings per diluted share)的指引修訂為 2.41 至 2.42 美元。此調整主要是由於第三季調整後 EPS 低於預期、美元兌英鎊匯率下滑,以及資產剝離交易的影響。
We also established guidance for fourth quarter adjusted EPS in a range of $0.55 to $0.56. This range includes a negative impact of $0.03 due to the change in the exchange rate from $1.30 to $1.22. Also, assuming a November 30 closing date for the divestiture transaction, our guidance includes a negative impact for December of $0.02. This reflects the decline in revenues and EBITDA from the divested facilities, offset partially by immediate synergies, reduced depreciation and interest expense savings. This guidance assumes an exchange rate of $1.22 per British pound sterling for the fourth quarter and a tax rate of 22%. Our financial guidance does not include the impact from any future acquisitions or transaction-related expenses.
我們也訂定第四季調整後 EPS 指引區間為 0.55 至 0.56 美元。此區間包含因匯率由 1.30 變動至 1.22 所造成的 0.03 美元負面影響。此外,若假設資產剝離交易於 11 月 30 日完成交割,我們的指引亦包含 12 月份 0.02 美元的負面影響。這反映了被剝離設施帶來的營收與 EBITDA 下滑,部分由立即的協同效益、折舊降低以及利息費用節省所抵銷。本指引假設第四季英鎊兌美元匯率為 1.22,稅率為 22%。我們的財務指引不包含任何未來收購或交易相關費用的影響。
This concludes our prepared remarks this morning and thank you for being with us. I'll now ask Matt to open the floor for your questions.
以上為我們今早的預先準備發言,感謝各位與會。接下來我會請 Matt 開放現場提問。
Operator
Operator
Thank you. (Operator Instructions). We will take our first question from John Ransom with Raymond James.
謝謝。(接線員指示)。我們的第一個問題來自 Raymond James 的 John Ransom。
John Ransom - Analyst
John Ransom - Analyst
Hi, good morning. Guys, I'm not used to being first in the queue, so this is a big day for me.
嗨,早安。各位,我不太習慣排在第一個提問,所以今天對我來說是個大日子。
Joey, I was just wondering in your long history in this industry, have you ever experienced problems filling de novo beds, and would you mind please just elaborating a little more on what the specific problems were that you flagged in those four hospitals and what you guys are doing to fix that? Thanks.
Joey,我想請教,在你這個產業的長期經驗中,你是否曾遇過新設(de novo)病床難以填滿的問題?也請你再多說明一下,你們在那四家醫院所指出的具體問題是什麼,以及你們打算如何解決?謝謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Pleasure, John. Ramping up the de novo beds, what we have discovered that is maybe more cumbersome than it had been in the past is getting through the regulatory approval and in some cases getting through some regulatory approval even at the county level. And our most recent example was the -- is our San Jose facility which I think we opened up in the first quarter of this year. But we did not receive its final two -- we did not receive permission on adult and child and adolescent placements until October. We thought we would have it within the first 60 days of opening and it took six months to get there. And so -- but since we got them at the first of October, the census has more than doubled at the facility. So we were just waiting on being able to take those patients from emergency rooms in the community.
很高興,John。關於新設(de novo)病床的爬坡(ramp up),我們發現可能比過去更棘手的是取得監管核准,在某些情況下甚至需要通過郡(county)層級的監管核准。我們最近的例子是——就是我們的聖荷西(San Jose)設施,我想我們是在今年第一季開幕的。但直到 10 月我們才拿到最後兩項——我們直到 10 月才獲准收治成人以及兒童與青少年安置(placements)。我們原本以為開幕後 60 天內就能取得,但實際花了六個月才完成。因此——不過自從 10 月初取得核准後,該設施的住院人數(census)已經增加一倍以上。所以我們其實只是一直在等能夠從社區的急診室接收那些病患。
So it got kind of hung up between the county, city, and state and that's what we've learned through the other three transactions -- the other de novos, is getting the regulatory approvals as quickly as possible and doing maybe more preliminary work ahead of the opening on getting those. But you have to get open to get licensed, to get your joint commission accreditation. And because we take placements of committed patients, you have more regulatory approvals to get through.
所以它有點卡在郡、市(city)與州(state)之間;而我們從另外三個交易——另外幾個新設(de novo)案子——學到的是,要盡可能快速取得監管核准,並且在開幕前就先做更多前置作業來取得這些核准。但你必須先開幕才能取得執照(licensed),才能取得聯合委員會(Joint Commission)的認證(accreditation)。而且因為我們接收的是被強制安置(committed)的病患,你需要通過更多監管核准。
So that's the only thing -- that's the main thing that we've seen in the ramping up of the facilities. And this week, we've had record censuses for the de novo group. And so, so it's basically just getting through the regulatory issues.
所以這就是唯一的——也是我們在設施爬坡過程中看到的主要問題。而本週我們的新設(de novo)群組創下最高住院人數紀錄。所以基本上就是把監管問題處理完。
John Ransom - Analyst
John Ransom - Analyst
Great. And then my other -- my follow-up and I'll get back in the queue is, if we take the 4Q numbers, I think what we're trying to do at least in our case is extrapolate into next year, our 4Q. And you've talked about your FX, you talked about the M&A. But in general, how should we think about seasonality? If we kind of level-set everything back to October 1 and use, say there's $100 of EBITDA, is that -- my understanding is fourth quarter is always a little seasonally light -- the back half of December. I mean, would fourth quarter not represent a quarter of the year, if everything were kind of level set to October 1?
很好。那我另外一個——追問一下,然後我就回到隊列後面:如果我們看第四季的數字,我想至少就我們而言,我們試著把第四季外推到明年。你談到了匯率(FX),也談到了併購(M&A)。但整體來說,我們應該如何看待季節性?如果我們把一切都拉回到 10 月 1 日作為基準,假設 EBITDA 是 100 美元,那麼——我的理解是第四季通常會因季節性而稍微偏淡——尤其是 12 月下半月。我是說,如果一切都以 10 月 1 日為基準,第四季是否不會代表全年四分之一?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
John, just in the general topic of seasonality, we've now seen 2015 and 2016 that the third quarter would be a little bit less than the first two quarters of the year. You are correct that once you get to about December 15 through about January 15 of the next year, that does -- because of the holidays, both Christmas and New Year's, the census does soften. And we're always anxious once we get into the new year to see how quickly it ramps back up. So that's how we see it.
John,就季節性這個一般性主題而言,我們在 2015 與 2016 都看到第三季會比前兩季略低。你說得沒錯,大約從 12 月 15 日到隔年 1 月 15 日,因為假期(聖誕節與新年),住院人數(census)確實會走弱。我們每次進入新年度後都會很關注它回升的速度。所以我們是這樣看的。
And then as you're building the model, please keep in mind, if you were to go back and look at the history of Acadia, our first quarter quite frankly because we have to start over on all the payroll taxes. There's several extra million dollars of expense that will occur in the first quarter as we meet the unemployment and the FICA taxes. So sometimes people miss that expense when they're looking at the first quarter in building their model.
另外在你建立模型時,請記得:如果你回頭看 Acadia 的歷史,我們第一季坦白說因為所有薪資稅(payroll taxes)都要重新起算,會有額外數百萬美元的費用在第一季發生,因為我們要繳納失業保險與 FICA 稅。有時候大家在看第一季、建立模型時會漏掉這筆費用。
John Ransom - Analyst
John Ransom - Analyst
Great. Thanks a lot.
很好。非常感謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Thanks.
謝謝。
Operator
Operator
And our next participant is Brian Tanquilut with Jefferies.
下一位提問者是 Jefferies 的 Brian Tanquilut。
Brian Tanquilut - Analyst
Brian Tanquilut - Analyst
Hey, good morning, guys. Joey, just a question on growth. As we think about the same-store going down to about 6.2% this quarter in the US, how should I think about bridging from 2016 with the bed adds that you're planning to put in place for 2017? And how that would translate into a growth rate?
嘿,各位早安。Joey,我有個關於成長的問題。當我們看到本季美國同店(same-store)成長降到約 6.2% 時,我應該如何思考從 2016 年銜接到 2017 年你們計畫新增的病床數?以及這會如何轉換成成長率?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
We're obviously -- obviously, our goal of being the best on same-facility growth exists today and will exist for 2017. And even though the third quarter was a little bit lower than our expectation, I think year-to-date, same-facility revenue is up about 8%, 7.7%. So we're having a terrific year this year and we've seen October since it's bounced back from the third quarter.
我們很明顯——很明顯,我們追求同院(same-facility)成長表現最佳的目標,現在存在,2017 年也會存在。即使第三季略低於我們的預期,我想年初至今同院營收大約成長 8%、7.7%。所以今年我們表現非常出色,而且我們看到 10 月已經從第三季回升。
We're going to build over 800 beds this year. And right now, it looks like we'll be doing the same -- at least the same number again next year. So the demand in bed build is out there. We recently just got CON approval here in Tennessee to expand our Murfreesboro facility by 80 beds, I think. And so, would take it from 120 to nearly 200 -- to 200 beds.
我們今年將建置超過 800 張病床。而目前看起來,明年至少也會做同樣——至少同樣的數量。所以病床建置的需求確實存在。我們最近剛在田納西州取得需求證明(CON)核准,將 Murfreesboro 設施擴增 80 張病床,我想是 80 張。這會讓它從 120 張增加到接近 200——到 200 張病床。
So we see the demand and the need to build the beds and we're going to be building beds in Wilmington, North Carolina and throughout, and Atlanta, Georgia. So the demand is there and so we're very optimistic that again next year, we will just have strong single-digit same-facility patient day growth and strong same-facility revenue growth.
所以我們看到建床的需求與必要性,我們也將在北卡羅來納州威明頓(Wilmington, North Carolina)以及各地、還有喬治亞州亞特蘭大(Atlanta, Georgia)建置病床。因此需求是存在的,我們非常樂觀,明年同樣會有強勁的同院病患日(patient day)單位數成長,以及強勁的同院營收成長。
Brian Tanquilut - Analyst
Brian Tanquilut - Analyst
And then, Joey, you mentioned earlier in your prepared remarks that you're not going to open a de novo until Q3 of 2017. So just help us if you don't mind -- how should we think about the difference between 2017 and 2016 considering that you also built 800 beds this year and I think if you're planning 800 next year, that's like a 7% growth in US beds. So what would be the difference in terms of your ability to fill those beds quickly next year versus this year?
另外,Joey,你先前在準備發言中提到,你們要到 2017 年第三季才會開設新設(de novo)。所以如果你不介意,請協助我們理解——考量你們今年也建了 800 張病床,而如果明年也規劃 800 張,那大概是美國病床數 7% 的成長。那麼在明年相較於今年,你們快速填滿這些病床的能力上,會有什麼差異?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Based upon what we see for next year, Brian, is that more of the beds will be going to existing facilities and less to de novos because they're coming on later in the year. But it appears right now, we have pretty good visibility into the joint ventures and it appears 2018 could be a banner year for joint ventures. We have, we'll probably before the end of the year, sign two letter of intents with new joint ventures. So it is just the timing of signing and reaching an agreement with your partner and getting the beds built. And so 2017, we'll have some in the back half of that year, but 2018 could be a banner year for the joint venture de novo beds.
Brian,依我們對明年的觀察,更多病床會配置到既有設施,較少配置到新設(de novo),因為新設會在年內較晚才陸續上線。不過目前看起來,我們對合資(joint ventures)的能見度相當不錯,而且看起來 2018 年可能會是合資的亮眼年度。我們可能在年底前與新的合資案簽署兩份意向書(letter of intent)。所以這主要是簽約時點、與合作夥伴達成協議的時點,以及把病床建好所需時間的問題。因此 2017 年會有一些在下半年,但 2018 年可能會是合資新設(de novo)病床的亮眼年度。
Brian Tanquilut - Analyst
Brian Tanquilut - Analyst
All right. Thank you, Joey. Thanks.
好的。謝謝你,Joey。謝謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Thank you.
謝謝你。
Operator
Operator
And we will now hear from AJ Rice with United Bank Systems.
接下來我們將聽取來自 United Bank Systems 的 AJ Rice 提問。
AJ Rice - Analyst
AJ Rice - Analyst
It's actually UBS, but anyway. On the UK, obviously, I understand the distractions with management and so forth. Is there -- obviously at times, there has been a little settlement over time since Brexit, I know it's still somewhat in a state of flux on the exchange side and the implications for the economy, but is the discussion with the NHS about what they hope to do, their posture toward this space, the number of off-loading of people outside the system, is all of that still the same in the dialogue you're having with them or has there been any change?
其實是 UBS,不過算了。關於英國,顯然我理解管理層等方面的干擾因素。想請問——顯然自英國脫歐以來,隨著時間推移有一些逐步落定的情況;我知道在交易所端仍有些處於變動之中,以及對經濟的影響。但你們與 NHS 討論他們希望怎麼做、他們對這個領域的立場、把人員移出體系外的卸載數量等,在你們與他們的對話中,這些是否仍然維持不變?還是有任何改變?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It's still on track, AJ, and similar to what we've experienced for the past three years there. So we're very, very bullish. We just need to get this transaction done. And it looks like it's going to be done by November 30 at the latest. And that will give us all of next year. Now in the UK, I think probably 80% to 90% of bed builds -- of bed additions there are going to be beds supporting same-facility growth.
AJ,一切仍按計畫進行,與我們過去三年在那裡的經驗相似。所以我們非常、非常看多。我們只需要把這筆交易完成。看起來最晚會在 11 月 30 日前完成。這樣我們就能擁有明年整整一年。現在在英國,我想大概 80% 到 90% 的床位建置——也就是床位增加——都會是支援同院成長的床位。
So we see that and just -- we just need to get the transactions, the noise of that away. We need to get the divestiture facilities spun out and let our operating team concentrate on running the facilities and not worried about which team they're going to be with or when the transaction's going to occur. So we're about to get a lot of clarity. But as far as NHS, we see no significant changes going in there.
所以我們看得到這點,而我們——我們只需要把交易的雜音排除掉。我們需要把要剝離的機構分拆出去,讓我們的營運團隊專注於經營機構,而不是擔心他們會跟哪個團隊、或交易何時會發生。所以我們即將獲得很大的清晰度。但就 NHS 而言,我們看不到任何重大變化。
AJ Rice - Analyst
AJ Rice - Analyst
Okay. And it sounds like you might have mentioned this just before I got on a couple minutes late. But when you think about taking the capital from the divested facilities in the UK, it sounds like you're primarily focused on redeploying that in the US. Is there any restriction on that, first of all? And then second, how fast do you think you could do that? You think you could, is there a potential that it could be in one transaction, is it multiple transactions? Should we think about it spreading over the year or how fast could it be redeployed?
好的。聽起來你可能在我晚了幾分鐘上線前就提到過。當你們考慮把英國已剝離機構的資金拿回來時,聽起來你們主要是聚焦把它重新部署到美國。首先,這樣做有任何限制嗎?其次,你覺得你們能多快做到?你覺得有可能用一筆交易就完成嗎,還是會是多筆交易?我們應該把它想成會分散在一年內進行,還是能更快重新部署?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It could be all of those. We think that by mid-year next year, we will have it deployed. There are three to five transactions that we know and that we have various stages of discussions that we could commit all the proceeds to those transactions in just one transaction, or it might be spread across two or three. So -- but right now, we have a lot of discussions going on with the larger transactions and so that we could deploy what we think is going to be about a net of $360 million that we could do it in one transaction.
以上情況都有可能。我們認為到明年年中就會部署完成。我們知道有三到五筆交易,且我們正處於不同階段的討論中;我們可以把所有收益在一筆交易中承諾投入到那些交易,也可能分散在兩到三筆。所以——但目前我們正就較大型的交易進行許多討論,因此我們可以把我們認為約為淨額 3.6 億美元的資金,在一筆交易中部署出去。
AJ Rice - Analyst
AJ Rice - Analyst
Okay. All right. Great. Thanks a lot.
好的。好。非常感謝。
Operator
Operator
And our next question comes from Frank Morgan with RBC Capital Markets.
下一個問題來自 RBC Capital Markets 的 Frank Morgan。
Frank Morgan - Analyst
Frank Morgan - Analyst
Good morning. Back on the issue of the shortfall in growth. Could you break it down, like attribute it -- maybe weighing between how much of this was just general weakness across the system versus the amount that we attributed to these de novos?
早安。回到成長缺口的問題。你能否把它拆解一下——例如歸因——也許衡量一下其中有多少只是整個系統的普遍疲弱, versus 我們歸因於這些新設(de novo)機構的部分有多少?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Two of the de novos are in the same-facility numbers. All four would be in total facility numbers, but two of those are in the same-facility and they did weigh on the, weigh down the growth there, but we're about to get it now that we've got all the regulatory approvals. As I mentioned earlier, it appears compared to 2015 and 2016 that the third quarter has low seasonality into it and we saw that happen even though our growth of -- our growth was still hospital facility leading growth, it was just a little bit less than what we wanted and it's a handful of facilities spread across the country and there's probably as many facilities, there's probably that many different reasons on why they didn't hit their growth targets for us, with one of those being the de novo and San Jose, they didn't have the regulatory approval.
四個新設(de novo)都會反映在總機構數的數字裡,但其中兩個會反映在同院(same-facility)的數字裡,而那兩個確實拖累了那裡的成長;不過我們現在即將改善,因為我們已取得所有監管核准。如我先前提到的,相較於 2015 與 2016 年,第三季呈現淡季特性較低,我們也看到這種情況發生;即便我們的成長——我們的成長仍由醫院機構帶動,只是比我們想要的略低一些。這是全國各地少數幾家機構的情況,而且可能有同樣多的原因解釋為何它們沒有達到我們的成長目標;其中一個原因就是 San Jose 的新設機構,因為他們尚未取得監管核准。
Frank Morgan - Analyst
Frank Morgan - Analyst
And the other three that were the de novos, do those all have the necessary licensure? I mean, are they now at that point like San Jose is?
那另外三個新設(de novo)都已取得必要的執照嗎?我的意思是,它們現在都像 San Jose 一樣到位了嗎?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes, they are. They have all the regulatory approvals. And as I mentioned earlier, the San's census this week has been at an all-time high and ramping nicely.
是的,都已取得。他們已拿到所有監管核准。而且如我先前提到的,本週 San 的住院人數(census)創下歷史新高,爬坡進展良好。
Frank Morgan - Analyst
Frank Morgan - Analyst
Got you. And that's just San Jose or is that at all the -- the other three as well?
了解。那只是 San Jose,還是也包括其他三家?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
All -- I'm talking about all of them.
全部——我指的是全部。
Frank Morgan - Analyst
Frank Morgan - Analyst
Okay. And then, I guess you started touching on this. I was just curious -- is there any, when you look across the portfolio, any regional variation or regional weakness or was it attributed more to the acute versus the RTC set?
好的。然後,我想你開始提到這點了。我只是好奇——當你們檢視整個投資組合時,有沒有任何區域差異或區域性疲弱?或者這更多是歸因於急性(acute) versus RTC 組合?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It was just general, Frank. It was both acute and RTC and it was spread from coast to coast. We spend a lot of time looking at it and going back and doing analysis on it and it was a handful of facilities across the country that had different reasons of why they didn't hit their numbers.
只是普遍性的,Frank。急性與 RTC 都有,而且從東岸到西岸都有。我們花了很多時間檢視,回頭做分析;結果是全國少數幾家機構因為各自不同的原因,沒有達到他們的數字。
Frank Morgan - Analyst
Frank Morgan - Analyst
And then finally, I want to make up sure I've got this right. You're saying that in 2017 that of the aggregate beds to be added for the year that there's a much lower percentage of pure de novo facilities versus expansion beds and therefore, expansion beds are much less disruptive in terms of what fill-up looks like, did I get that right?
最後,我想確認我理解正確。你是說在 2017 年,全年新增床位的總量中,純新設(de novo)機構的占比會低很多,更多是擴建床位;因此擴建床位在填床(fill-up)的干擾程度上要小得多。我理解對了嗎?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
You got that right.
你理解正確。
Frank Morgan - Analyst
Frank Morgan - Analyst
Thank you.
謝謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Thanks.
謝謝。
Operator
Operator
Our next participant is Whit Mayo with Robert Baird.
下一位提問者是來自 Robert Baird 的 Whit Mayo。
Whit Mayo - Analyst
Whit Mayo - Analyst
Hey, thanks. Looking at the UK results, the same-store looks pretty good with same-store EBITDA up about 10%. And when I back into the new store UK hospitals which presumably is mostly Priory, it looks like you had maybe a $5 million EBITDA slip sequentially. Revenues were down maybe $30 million sequentially. Is that where the distraction came from? The margins just look consistent, so I'm just struggling a little bit to put the puzzle together.
嗨,謝謝。看英國的結果,同店表現看起來相當不錯,同店 EBITDA 約成長 10%。而當我倒推英國的新店醫院(推測主要是 Priory)時,看起來你們的 EBITDA 可能季比下滑約 500 萬美元。營收季比可能下滑約 3,000 萬美元。干擾是從這裡來的嗎?因為毛利率看起來一致,所以我有點難把整個拼圖拼起來。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
I think the biggest missing piece of the puzzle is that the $20 million of synergies will accrue to the Priory side. And when you look at their numbers, you need to be thinking about $12 million of expenses coming out and what that does to the margin for the Priory side. Frank, I have not looked at the revenues from the second quarter to the third quarter the way you did, but we're very bullish on what Priory has done and what they will do. So -- but I just haven't looked at that one indicator. But I do know the $20 million of synergies accrued to the Priory side.
我認為這個拼圖中最大缺失的一塊是:2,000 萬美元的綜效會歸到 Priory 端。當你看他們的數字時,你需要把 1,200 萬美元的費用移除,以及這對 Priory 端毛利率的影響納入考量。Frank,我沒有像你那樣去看第二季到第三季的營收變化,但我們非常看多 Priory 已經做出的成果以及他們將會做出的成果。所以——但我只是沒有看那個單一指標。不過我確實知道那 2,000 萬美元的綜效是歸到 Priory 端的。
Whit Mayo - Analyst
Whit Mayo - Analyst
Got it. And maybe just -- maybe you commented on this and I missed it, just the seasonality in the UK. Is there anything unusual about the third quarter? I mean, we're all sort of accustomed to how things progress over here.
了解。也許——也許你有評論過但我漏聽了,關於英國的季節性。第三季有什麼不尋常之處嗎?我的意思是,我們都大致習慣這邊的進展節奏。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Okay. Well, there is some seasonality in the UK that we found out is that -- so they like to take the whole month of August off as a holiday. So whenever everybody in the UK including government workers are on holiday, they can slow down the admission process for the patients. So that's the only thing unique that we found.
好的。英國確實有一些季節性,我們發現的是——他們喜歡把整個 8 月都放假當作假期。所以當英國所有人(包括政府員工)都在休假時,病患的收治流程可能會放慢。這是我們發現唯一比較特別的地方。
Whit Mayo - Analyst
Whit Mayo - Analyst
Got it. And I totally get the distraction in the UK, I think most people can understand it. Do you think that perhaps to focus, having to take your hands off the wheel in the US may have had an impact to operations here? I mean it's just a theory, but I'm just kind of curious your perspective just that that distraction may have spilled over to the US operations.
了解。我完全理解英國那邊的干擾,我想大多數人都能理解。你覺得也許為了聚焦,你們在美國這邊不得不把手從方向盤上移開,可能對這裡的營運造成影響嗎?我的意思是這只是個假設,但我想聽聽你的看法:那種干擾是否可能外溢到美國的營運。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It may have a little bit, Whit. Obviously senior management here was -- we spend a lot of time, a lot of hours on the UK and probably some of those would have been spent back here on the US operations. So probably a little bit.
可能有一點,Whit。顯然這邊的高階管理層——我們在英國花了很多時間、很多工時,而其中一些本來會花在美國的營運上。所以可能有一點。
Whit Mayo - Analyst
Whit Mayo - Analyst
Okay. And maybe one last one here, just can you give us in size the headwind year-to-date from the de novos just as we think about tailwinds into 2017 and maybe just comment on the progression of earnings within a typical de novo? How much do you lose on average, for how long when you break-even and how long to sort of mature into maybe a high teens margin or something?
好的。最後一個問題,你能否提供一下截至目前(year-to-date)新設(de novo)帶來的逆風規模,好讓我們思考 2017 年的順風?另外也請評論一下典型新設機構的獲利爬坡:平均會虧損多少、會持續多久、何時損益兩平,以及需要多久才能成熟到例如十幾個百分點的毛利率之類?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
The four de novos that we talk about, I think, Whit, I think they lost $1.5 million in the third quarter and we'd budgeted them to be on a run rate of $2.5 million earnings. So that's what it cost us in the fourth quarter, I mean, third quarter. If we have them breakeven by the end of the year, that would be great and contributing next year. So these facilities do have the potential to get to our facility margins. So starting January 1, 2017, it probably would take 24 months to get to that high level. But now that we have all the regulatory approval and the census is ramping, we just got to execute on those four de novos and so we'll quit carrying them. So we're very positive looking of what will happen in 2017 with the de novos.
我們談到的那四家新設點(de novo),我想,Whit,我想它們在第三季虧損了150萬美元,而我們原本編列的預算是希望它們能達到每年250萬美元獲利的運行水準(run rate)。所以這就是它在第四季——我是說第三季——對我們造成的成本。如果我們能在年底前讓它們損益兩平,那就很棒了,並且在明年開始貢獻。因此,這些機構確實有潛力達到我們的機構利潤率。若從2017年1月1日開始算,可能需要24個月才能達到那樣的高水準。但現在我們已取得所有監管核准,入住人數(census)也在爬升,我們只需要把這四家新設點執行到位,這樣我們就不必再承擔它們的拖累。所以我們對2017年新設點的表現非常正面。
Whit Mayo - Analyst
Whit Mayo - Analyst
Did you have a similar level of startup cost in the second quarter or the first quarter? Again, I'm just trying to think year-to-date --
你們在第二季或第一季也有類似水準的開辦成本嗎?我只是想從年初至今的角度來思考——
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
I do not have the second quarter number here.
我這裡沒有第二季的數字。
Whit Mayo - Analyst
Whit Mayo - Analyst
It's okay. I can follow up with you. Okay.
沒關係。我可以再跟你追問。好。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes.
是。
Whit Mayo - Analyst
Whit Mayo - Analyst
Thanks, Joey.
謝謝你,Joey。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes. Thank you.
是。謝謝。
Operator
Operator
We will now hear from Gary Lieberman with Wells Fargo.
接下來我們將聽取來自富國銀行(Wells Fargo)的Gary Lieberman提問。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Good morning, thanks for taking the question. I think you said October bounced back to 6.7% --
早安,謝謝讓我提問。我想你說10月回升到6.7%——
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes.
是。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
-- the 6.2% same-store patient day growth in the third quarter. That's still a little bit below, I think it was 7.5% in the first half of the year, which was quite strong. Do you think you can get back to that or do you think you're kind of where it's going to settle out?
——相較於第三季同店病患日(patient day)成長6.2%。這仍然略低於我記得上半年大約7.5%的水準,那相當強勁。你覺得可以回到那個水準嗎?還是你覺得大概就會落在目前這個區間?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
We're working as hard as we can to get back to that other number. So with a little luck and -- you always need a little luck, the 6.7%, can we grow that into the 7%, that's our goal. But once again, we don't know how December 15 through December 31 will impact us.
我們正盡最大努力回到那個數字。所以再加上一點運氣——你總是需要一點運氣——6.7%能不能拉升到7%,那是我們的目標。但再一次,我們不知道12月15日到12月31日會對我們造成什麼影響。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Okay. But you feel that there's nothing structural that has changed...
了解。但你覺得沒有任何結構性因素改變……
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Absolutely not. Absolutely not.
絕對沒有。絕對沒有。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Got it. And then you've talked about in the past potentially doing a larger deal in the first half of 2017. It sounds like maybe your thinking on that has changed a little bit and I assume you wouldn't want to issue equity for any type of deal based on where the stock is. Can you just talk about that?
明白。然後你們過去談過可能在2017年上半年做一筆較大的交易。聽起來你們對此的想法可能有些改變,而且我猜基於目前股價水準,你們也不會想為任何交易發行股權。你能談談這點嗎?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
We do not plan on using stock to do the transaction, that we think the proceeds from the sales and any -- and our access to our revolver can make that happen. And we still hope, and it's our goal to do something in the first six months of next year, to get this money redeployed.
我們不打算用股票來做這筆交易;我們認為出售資產的所得,以及——再加上我們動用循環信貸額度(revolver)的能力,就能促成這件事。我們仍然希望,而且這也是我們的目標,在明年前六個月做成一件事,把這筆資金重新部署。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Got it. And can you just update us on your thoughts on leveraging kind of target leverage ratios and if you'd be more -- or less likely to use debt here?
了解。你能更新一下你們對槓桿的想法,例如目標槓桿比率,以及你們在這裡會更——或更不——傾向使用負債嗎?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
We still want to be below 5.5 times, closer to 5 times. And as you've noticed this year, our cash from operations has grown nicely. So on the debt side, we want to be under 5.5 times leveraged and also redeploy the money that we have.
我們仍希望低於5.5倍,更接近5倍。而且如你今年所見,我們的營運現金流成長得不錯。所以在負債方面,我們希望槓桿維持在5.5倍以下,同時也把我們手上的資金重新部署出去。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Okay. And then maybe finally, as we get closer to 2017, can you comment on how your contracting is going and how that might help you benefit from the elimination of the IMD exclusion for the managed Medicaid population?
好。最後,隨著我們更接近2017年,你能評論一下你們的合約談判(contracting)進展如何,以及這可能如何幫助你們受益於針對管理式Medicaid族群取消IMD排除條款(IMD exclusion)?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Contracting for us, we do not do any national contracting. We have, in the UK, locked down the 1% for the coming year. So that is done, so -- but here in the US, I think our contracting, we expect the states on the Medicaid side still to be in that 1% range. Medicare I think once again will be in that 2% -- maybe 2.25% range and then the commercial side, we're still achieving the 4% to 6% rate increases. But so, our contracting is similar to what we've been doing in the previous years.
就我們而言,合約談判方面,我們不做任何全國性(national)的合約。在英國,我們已把明年的1%鎖定下來,所以那已經完成了——但在美國這邊,我認為在Medicaid端,我們預期各州仍會在約1%的區間。Medicare我想同樣會在約2%——也許2.25%——的區間;而商業保險端,我們仍能達成4%到6%的費率調升。所以,我們的合約談判與過去幾年做法相近。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
I guess, I was referring more to having the managed Medicaid plans in networks that you need to have --
我想我指的是,讓你們需要納入網絡(in network)的管理式Medicaid計畫——
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Oh, managed Medicaid?
喔,管理式Medicaid?
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Yes, the population, in order to get the IMD population.
是,為了取得IMD族群(IMD population),你們需要的那個族群。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Okay. We have made Brent Turner, our expert here. So he will give you the answer to that.
好。我們已讓Brent Turner來負責,他是我們這方面的專家。所以他會回答你這個問題。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Yes.
是。
Brent Turner - President
Brent Turner - President
Well, yes absolutely. Some of the states have deferred whereas the July 1, 2016 effect of the IMD change inside the managed Medicaid plans -- some, it was optional this year. We expect that to be more fully embraced in 2017. And so absolutely, our efforts as we, not just contracting with the payers, but also just educating and updating the referral sources to ensure that much like all the other patients, they are sending us these managed Medicaids in 2017 as well. So that's absolutely in our plans.
嗯,是的,絕對是。有些州已延後;原本IMD變更在管理式Medicaid計畫內於2016年7月1日生效——其中一些州今年是選擇性(optional)實施。我們預期2017年會更全面採行。因此,絕對地,我們的努力不僅是與付款方(payers)簽約,也包括教育並更新轉介來源(referral sources),以確保就像其他所有病患一樣,他們在2017年也會把這些管理式Medicaid病患轉介給我們。所以這絕對在我們的計畫之中。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
So should that benefit start on January 1 or is it going to phase in over the course of the year?
所以這個效益應該會從1月1日開始,還是會在一年當中逐步導入?
Brent Turner - President
Brent Turner - President
I think you're going to see, it's probably we got -- probably began a little bit. Again it's market-specific in 2016, but fully it's going to be a lead-in benefit. It should begin to see it in January. And certainly if there is plans at July 1 fiscal year for the state, if some of will match up with that, it will be somewhat gradual and continuous impact over 2017.
我想你會看到,它可能——我們已經——可能已經開始有一點了。再說一次,2016年是依市場而定,但全面來看,它會是一個逐步帶入(lead-in)的效益。你應該在1月就開始看到。而且如果某些州是7月1日作為財政年度起點、計畫也與之對齊,那麼在2017年會是較為漸進且持續的影響。
Gary Lieberman - Analyst
Gary Lieberman - Analyst
Okay. Great. Thanks a lot.
好。很好。非常感謝。
Operator
Operator
Our next question comes from Ann Hynes with Mizuho Securities.
下一個問題來自瑞穗證券(Mizuho Securities)的Ann Hynes。
Ann Hynes - Analyst
Ann Hynes - Analyst
Hi. Thanks. I just need a clarification on the US same-store revenue. I know you said part of it was to the two de novos. You did mention other facilities were having a handful of issues. Can you give us more specifics on those facilities? And also, you did say that there was overall weakness. Do you think that weakness is due to seasonality, and if it is, do you think there's maybe more seasonality in your addiction business versus your historical hospital business?
嗨,謝謝。我想釐清一下美國同店營收。我知道你說其中一部分是因為兩家新設點(de novos)。你也提到其他機構有少數幾個問題。你能更具體說明那些機構的情況嗎?另外,你確實說到整體偏弱。你認為那個偏弱是季節性造成的嗎?如果是,你覺得你們的成癮業務相較於你們過去的傳統醫院業務,是否有更強的季節性?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Ann, that was a lot of questions in that one question. First, the -- if you look at the third quarter this year and the third quarter last year, those two right now appear to the softest quarters of the years. So it appears that maybe there is seasonality in that quarter. So we'll just have to wait and see.
Ann,你這一題裡面問了很多問題。首先——如果你看今年第三季和去年第三季,這兩個目前看起來是全年最疲弱的季度。所以看起來那一季可能確實有季節性。我們只能再觀察看看。
Reasons for not hitting the growth could be that we didn't get the beds on line. We had expectations that beds would be on line the first of the quarter and they came on mid-quarter or towards the end of the quarter, so we missed some patients there. It could be various, as the de novo, we were waiting on a regulatory approval there for the San Jose facility. So it's various reasons like that.
沒有達到成長的原因可能是我們沒有把床位如期上線。我們原本預期床位會在該季一開始就上線,但實際是在季中或接近季末才上線,所以我們因此少收了一些病患。也可能是各種原因;例如新設點方面,我們在聖荷西(San Jose)機構那邊還在等監管核准。所以大概是這類各種原因。
Now we do have isolated shortages. If there is anybody on the call that wants to move to Butte, Montana, we can make you a mental health tech. But -- so, there -- it was different reasons for the facilities not growing and hitting their patient day growth that we thought they would in the third quarter.
另外我們確實有零星的人力短缺。如果電話會議上有人想搬去蒙大拿州的比尤特(Butte, Montana),我們可以讓你當一名心理健康技術員(mental health tech)。但——所以,各機構沒有成長、未達到我們在第三季預期的病患日成長,原因各不相同。
Ann Hynes - Analyst
Ann Hynes - Analyst
Okay. And my follow-up question, has a few questions. And I think it's an important question going into 2017 because obviously this has been a rush doc year to date. And when I look at 2017 consistent estimates, they're pretty much all over the place. And I know you don't want to provide guidance now. But any guidance you can give us to the moving parts so consistent estimates can get aligned. So it doesn't continue to be an overhang for next year, probably would be very good.
好。我的追問其實有幾個問題。我認為這對進入2017年很重要,因為顯然今年迄今一直是個「rush doc」的一年。而當我看2017年的市場一致預估(consensus estimates)時,幾乎差異很大。我知道你們現在不想提供指引(guidance)。但你們若能就影響因素(moving parts)提供一些方向,讓一致預估能更對齊,避免明年持續成為壓力,應該會很有幫助。
And the things that I view as, when I look at my model as the moving parts would be, how should we view as like the ramp-up of synergies going into 2017 in the UK? With the UK, you said they're still having issues. Do you expect that to improve throughout 2017? Is that maybe first half of 2017, you still expect these issues? And also the redeployment of proceeds because -- when I look at the estimates, it looks like some people will have some acquisition assumptions in your model. And obviously there is going to be a timing issue there. So should we do that more like, I think you said the second half, but any guidance you can give would be helpful.
以我自己的模型來看,我認為影響因素會是:我們應該如何看待英國在2017年的協同效益(synergies)爬升(ramp-up)?就英國而言,你說他們仍有一些問題。你預期這些問題在2017年會逐步改善嗎?還是可能在2017年上半年仍會有這些問題?另外還有出售所得的重新部署(redeployment),因為——當我看那些預估時,看起來有些人會在你們的模型裡假設有併購。而顯然那裡會有時點(timing)問題。所以我們是否應該把它視為更像是——我想你說的是下半年——但你能提供的任何方向都會有幫助。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Okay, well, we're still putting together our -- we haven't totally finalized our 2017 budget. So that makes it a little bit more difficult. We will use $1.22 as the exchange rate for next year. We do expect to have the proceeds invested by July 1 of next year and so that would be something there.
好,我們目前仍在彙整——我們尚未完全定案 2017 年預算,所以這讓事情稍微更困難一些。我們明年將以 1.22 美元作為匯率。我們確實預期在明年 7 月 1 日之前把這些款項的收益完成投資部署,因此那會是其中一個重點。
The synergies, we will -- the synergy, the $20 million of synergies --
關於協同效益,我們將——協同效益,也就是 2,000 萬美元的協同效益——
Ann Hynes - Analyst
Ann Hynes - Analyst
Yes.
是。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
I think by the end of the year, we will be on a close to a $10 million run rate maybe, if everything goes well. And by the end of the third quarter this year and by the end of the first quarter next year, we should be in the mid-teen. And I think we will have them all done by the beginning of the fourth quarter next year. So the synergies will come rather rapidly once the transaction closes.
我認為到今年年底,如果一切順利,我們可能會接近 1,000 萬美元的年化執行率。到今年第三季末以及明年第一季末,我們應該會在 1,500 萬美元左右的區間。我想我們會在明年第四季初之前把它們全部完成。因此,一旦交易完成,協同效益會相當快速地顯現。
So -- and then we have internally discussed about, since there are some moving parts to this that we may find a different forum to get that communicated out to you all to help you with your models and your assumptions and the timing of acquisitions, so that's all still under discussion. But those are a couple of things on the synergies, redeployment of the capital, that sort of thing, that we can give you today, but we're still working through all that.
所以——另外我們內部也討論過,因為這裡面有一些變動因素,我們可能會找一個不同的場合把這些內容對外溝通給各位,協助你們在模型、假設以及併購時點上做判斷;這些都還在討論中。不過就協同效益、資本再部署之類的事項,我們今天能提供的就是這幾點,但我們仍在把所有細節梳理完成。
Ann Hynes - Analyst
Ann Hynes - Analyst
Okay. That's very helpful.
好的。這非常有幫助。
Operator
Operator
And we will now hear from Chris Rigg with Susquehanna Financial Group.
接下來我們將聽取來自 Susquehanna Financial Group 的 Chris Rigg。
Chris Rigg - Analyst
Chris Rigg - Analyst
Good morning, guys. Hopping on late here, but hopefully you can touch on these questions. So just looking at the CapEx year-to-date, roughly $250 million, if I assume that about 2% of that is just pure maintenance CapEx and then I look at the bed additions, plus the de novo beds, that comes out to roughly $300,000 per bed. I'm just trying to get a sense for what are the current numbers in terms of adding a bed or adding beds to an existing facility versus what it costs to develop a de novo site/beds? Thanks.
各位早安。我比較晚才加入,但希望你們能回應這些問題。就今年迄今的資本支出(CapEx)來看,大約 2.5 億美元;如果我假設其中約 2% 是純維護性資本支出,然後再看新增床位以及新設(de novo)床位,換算下來大約是每床 30 萬美元。我想了解的是,目前新增床位或在既有機構增加床位的成本,與開發一個全新據點/新設床位的成本,各自大概是多少?謝謝。
David Duckworth - CFO
David Duckworth - CFO
Yes. Chris, this is David. We've seen a greater mix this year. We talked about the de novo beds. That certainly has a higher cost per bed. We've also seen a greater mix of acute beds this year. So you're right, maintenance CapEx is at the kind of 2.5%, to 2.5% level for this quarter. It was 2.5% of revenue or $18.5 million. The rest of the CapEx would relate to expansion CapEx. And for that, we've seen a greater mix of acute and de novo beds. So that does tend to be at a higher cost per bed. So that's -- yes, hopefully that answers your question there, Chris?
是的,Chris,我是 David。今年我們看到更高比例的組合變化。我們談過新設(de novo)床位,那確實每床成本較高。今年我們也看到急性床位的占比提高。所以你說得對,本季維護性 CapEx 大約在 2.5% 左右;也就是營收的 2.5%,或 1,850 萬美元。其餘的 CapEx 會與擴張性 CapEx 有關。而在這部分,我們看到急性與新設床位的占比更高,因此每床成本確實會偏高。希望這樣能回答你的問題,Chris?
Chris Rigg - Analyst
Chris Rigg - Analyst
Sort of. I guess just if we spike out the de novo beds, what is the right way to think about bed additions for the acute care beds in terms of cost?
算是有。不過我想問的是,如果把新設(de novo)床位拆開來看,對於急性照護床位的新增,在成本上應該怎麼思考才比較正確?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Sure.
當然。
Chris Rigg - Analyst
Chris Rigg - Analyst
I know, it's really hard to generalize, but...
我知道這很難一概而論,但……
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Let me help you here, Chris. On the new beds, the de novo beds, they're going to cost between $250,000 and $300,000 per bed because you're building a --
Chris,我來補充一下。新床位、也就是新設(de novo)床位,每床成本大約會在 25 萬到 30 萬美元之間,因為你是在興建一個——
Chris Rigg - Analyst
Chris Rigg - Analyst
Okay.
好的。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
-- whole brand-new plant, all the ancillary services, administration, the infrastructure, the land, that's basically what is costing us today. And it varies by where in the country you're building. The bed builds to existing facilities, that's still going to be around $150,000. It may -- if it's having to go on the second floor, it can jump up to $175,000 or if it's just on the first floor, it might be $125,000. So those are the best numbers that we have today on what it's costing us per bed for our bed additions.
——全新的廠房,包含所有輔助服務、行政、基礎設施、土地,基本上這些就是我們目前的成本來源。而且會因為你在全國哪個地區興建而有所不同。至於在既有機構增建床位,每床大約仍會在 15 萬美元左右;如果必須蓋在二樓,可能會跳到 17.5 萬美元;如果只是蓋在一樓,可能是 12.5 萬美元。以上就是我們目前掌握的、每床新增的最佳成本數字。
Chris Rigg - Analyst
Chris Rigg - Analyst
Okay. That's very helpful. And then to change gears and move over to the resident (44 -- 42) expert on IMD -- Brent, I don't know if you've ever looked into this, but coming from -- if I'm looking at sort of the Medicaid Managed Care from that angle, they would say that a lot that of the mentally ill individuals reside in what's known as the aged, blind and disabled population, most of whom still are not covered by Managed Care. So -- and it is growing obviously. But when we think about sort of near-term benefits from IMD, is it your view that you probably don't see a big move in profits over the short term until you have the fee-for-service population also be included in the exclusion? Thanks.
好的,這非常有幫助。接著我想換個話題,請教一下 IMD 的常駐(44——42)專家——Brent,我不知道你是否研究過這個,但從 Medicaid 管理式照護(Managed Care)的角度來看,他們會說許多精神疾病個案其實屬於所謂的老年、失明與身心障礙(aged, blind and disabled)族群,而其中大多數目前仍未納入管理式照護。所以——而且這個族群顯然正在成長。但當我們思考 IMD 在短期內帶來的效益時,你的看法是否是:在按服務計費(fee-for-service)族群也被納入該排除條款之前,短期內可能不會看到獲利有很大的變化?謝謝。
Brent Turner - President
Brent Turner - President
Yes, I think, Chris, I mean, your point is absolutely valid that there's a separation between in effect the dual-eligible and the expanded Medicaid population. However, the dual-eligible population, right now even under-65 would be -- we would receive Medicare reimbursement for them and we have not seen a trend for that shifting into the managed Medicaid. So net-net, the increase driven by the IMD should be a positive both on volume and consistent with our other state-by-state Medicaid rates.
是的,Chris,我認為你的觀點完全正確:實際上,雙重資格(dual-eligible)族群與擴大 Medicaid 族群之間確實存在區隔。不過,雙重資格族群目前即使是 65 歲以下——我們仍會收到 Medicare 的給付,而且我們尚未看到這部分有轉向管理式 Medicaid 的趨勢。因此整體而言,由 IMD 所帶動的增加,無論在量的面向,或是與我們各州 Medicaid 費率一致性的面向,都應該是正向的。
Chris Rigg - Analyst
Chris Rigg - Analyst
Great, thanks a lot.
很好,非常感謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes.
是。
Operator
Operator
Our next participant is Charles Haff from Craig-Hallum.
下一位提問者是來自 Craig-Hallum 的 Charles Haff。
Charles Haff - Analyst
Charles Haff - Analyst
Hi, thanks for taking my questions. Most of them have been asked and answered. I wanted to touch on CRC a little bit, what kind of trends you saw in the third quarter for the former CRC assets. And the opioid addiction growth rate I think is trending at about 18% this year, according to the CDC. How do you see that kind of unfolding as being a tailwind for your business in 2017?
嗨,謝謝讓我提問。我的大部分問題都已經被問過並回答了。我想稍微談一下 CRC,想了解第三季你們在原 CRC 資產上看到哪些趨勢。另外,根據 CDC 的資料,阿片類藥物成癮的成長率今年大約在 18% 左右。你們怎麼看這件事在 2017 年會如何發展,並成為你們業務的順風?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Great question. The addiction side of our business in the specialty facility area was a little soft. However, our other specialty facilities they -- they did very well during the quarter. Our CTC facilities that treat the opiates, in the states that we're in, we're seeing demand and we're going to be doing some de novos in other states where we've been able to impact the legislature so that we can do that. So we've -- we're very -- this absolutely is a very needed service. This is probably the fastest growing piece of the mental health side, addiction side and we're trying to meet that and meet our community's needs and we would look at an acquisition in this space. We've made those over the past two years, additional acquisitions in this space. So the opioid addiction is not abating and we see it as a tremendous growth opportunity for us.
問得很好。我們在專科機構領域的成癮業務表現稍微偏弱;不過,我們其他的專科機構在本季表現非常好。我們的 CTC 機構(治療阿片類藥物)在我們所在的州看到需求,而且我們也會在其他州做一些新設(de novo),在那些州我們已能影響立法機關,使我們可以這麼做。所以——我們非常——這絕對是一項非常需要的服務。這可能是心理健康面向、成癮面向中成長最快的一塊,我們正努力滿足需求、滿足社區需要,而且我們也會考慮在這個領域進行併購。過去兩年我們已在這個領域做了額外的併購。因此,阿片類藥物成癮問題並未緩解,我們視其為對我們而言極大的成長機會。
Charles Haff - Analyst
Charles Haff - Analyst
Okay. And on acquisitions there, would it be in-network acquisitions or would it be out-of-network acquisitions that you would -- or it would be all the above?
好的。那在這方面的併購,會是網內(in-network)併購,還是網外(out-of-network)併購——或者兩者都會?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It would be in-network.
會是網內(in-network)。
Charles Haff - Analyst
Charles Haff - Analyst
Okay. And then when you think about bed additions for next year, would some of those bed additions be to the addiction side of your business?
好的。那再談到明年的床位新增,你們明年的部分新增床位會用在成癮業務這一塊嗎?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes, there is. There is some bed builds to the addiction side.
是的,會。有一部分床位增建會用在成癮業務。
Charles Haff - Analyst
Charles Haff - Analyst
Okay, great. And then just lastly, on the use of the $360 million of net proceeds -- it sounds like you can go a lot of different directions. Is it kind of coming down to price and kind of your return on invested capital model and decision making there? Or are there other factors such as geographic gaps or product gaps and so forth? And can you tell us what acquisition prices are kind of trending at in the US right now? That's my last question. Thank you.
好的,很好。最後一個問題,關於 3.6 億美元淨收益的運用——聽起來你們有很多不同方向可以走。最後是否主要取決於價格,以及你們的投資資本報酬率(ROIC)模型與決策?還是也會考量其他因素,例如地理版圖缺口或產品缺口等等?另外,你們能否談談目前美國的併購價格大概呈現什麼趨勢?這是我最後一題,謝謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Okay. We're not focused on trying to do geographic acquisitions or -- and we know of no new product lines that we would want to add to the company. The product lines that we have now, the service lines now are where we would be spending our money. So we would add to your list of what are we looking for is absolutely the best use, the accretive use of our money. But we would also be looking at the quality of the programs of that asset that we would be acquiring and the -- long-term growth rates for that acquisition and how we could make it a stronger facility and make it more valuable to our shareholders. So those would also be things that we would be looking at.
好的。我們並不著重於做地理型併購——而且我們也不知道有任何我們想新增到公司裡的新產品線。我們目前擁有的產品線、服務線,就是我們會投入資金的方向。所以,在你列出的條件之外,我們還會補充:我們絕對會尋找資金最好的用途、能帶來增益(accretive)的用途。但我們也會看我們要收購資產的方案品質,以及該收購案的長期成長率,並評估我們如何能把它做成更強的機構、讓它對股東更有價值。這些也都是我們會考量的因素。
Charles Haff - Analyst
Charles Haff - Analyst
And on the pricing side?
那在定價方面呢?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Pricing is now in the -- we're pricing in the low -- I mean not low, high-single digits, that is no longer in the double-digits. It would take something pretty attractive for us to go above 10 times.
定價現在在——我們的定價在低——我是說不是低,是高個位數,也就是不再是雙位數。要讓我們出到 10 倍以上,得有相當有吸引力的標的才行。
Charles Haff - Analyst
Charles Haff - Analyst
Thank you.
謝謝。
Operator
Operator
We will now hear from Kevin Fischbeck with Bank of America Merrill Lynch.
接下來我們將聽取美國銀行美林(Bank of America Merrill Lynch)的 Kevin Fischbeck 提問。
Joanna Gajuk - Analyst
Joanna Gajuk - Analyst
Good morning. This is Joanna Gajuk filling for Kevin. Thanks for taking the question here. Most of them were asked, but just a follow-up of the IMD exclusion commentary, where you're saying that it's taking some time to kind of postpone this until next year. But was there any change, any traction so far this year or it's pretty much only handful maybe update, but kind of made that decision this year.
早安。我是 Joanna Gajuk,代 Kevin 發問。謝謝讓我提問。大部分問題都已被問過了,但我想就你們對 IMD 排除條款的評論追問一下:你們說這需要一些時間,可能會把它延後到明年。但今年到目前為止是否有任何變化、任何進展?還是說基本上只有少數更新,但你們今年就做了那個決定。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes, Joanne, there's definitely, we saw our managed Medicaid volumes increase Q3 of 2016 over Q3 of 2015. So we're seeing some effect. It's hard to say how much of it is just due to the IMD. There's obviously been a couple of states where we have nice concentration of facilities that have done the delayed implementation of the ACA expansion. So again there's definitely not been a full effect for the IMD. And again, we look to see more of that throughout 2017.
是的,Joanne,確實如此。我們看到 2016 年第三季的管理式 Medicaid 量較 2015 年第三季增加,所以我們看到一些效果。很難說其中有多少純粹是 IMD 所致。顯然有幾個州,我們的機構集中度不錯,而他們延後實施 ACA 擴張。因此,IMD 的完整效果確實還沒有完全顯現。我們也預期在 2017 年會看到更多這方面的影響。
Joanna Gajuk - Analyst
Joanna Gajuk - Analyst
Right, that makes sense. And with DAAT, I know you've been saying that you're not seeing shortages of psychiatrists. Maybe there are some states, but then how would you think sort of the -- that kind of point of view which changed with IMD exclusion, would that create sort of maybe incremental pressure or not finding enough psychiatrists in some of these markets where you might have increased volumes? Are you planning sort of ahead of that, kind of secure maybe, doctors or anything you're kind of doing in preparation for those changes coming next year?
對,這很合理。那關於 DAAT,我知道你們一直說沒有看到精神科醫師短缺。也許有些州會有,但如果 IMD 排除條款帶來的那種觀點改變,是否可能在你們病患量增加的某些市場造成額外壓力,例如找不到足夠的精神科醫師?你們是否有提前規劃,例如先確保醫師人力,或為明年的變化做任何準備?
Brent Turner - President
Brent Turner - President
Again, I think if you go back to the data we gave around our ability to get to recruit psychiatrists across the country, we've recruited almost 150 year-to-date. So the IMD effect we do not have any concern that that driver is going to be offset by our ability to recruit physicians. We have a good team in our physician recruiting and they're doing a great job, and we don't see that as a limiting factor.
再說一次,我想如果你回頭看我們提供的數據,關於我們在全國招募精神科醫師的能力,我們今年迄今已招募將近 150 位。因此,對於 IMD 的影響,我們完全不擔心會因為我們招募醫師的能力而被抵銷。我們的醫師招募團隊很強,做得非常好,我們不認為這會成為限制因素。
Joanna Gajuk - Analyst
Joanna Gajuk - Analyst
Great. And just sort of -- the last quick question and a follow-up. So I did -- did I hear right when Joey was talking about sort of next year kind of view around the organic growth. So you were saying that you sort of feel confident that can grow high single digits organically?
很好。最後一個快問與追問:所以我——我有沒有聽對,Joey 在談到明年對有機成長的看法時,你們是說你們相當有信心有機成長可以達到高個位數?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
That is correct.
沒錯。
Joanna Gajuk - Analyst
Joanna Gajuk - Analyst
Great. Thank you so much.
太好了。非常感謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes.
是。
Operator
Operator
And we will now hear from Ana Gupte with Leerink Partners.
接下來我們將聽取 Leerink Partners 的 Ana Gupte 提問。
Ana Gupte - Analyst
Ana Gupte - Analyst
Yes. Hi. Thanks for taking my question. Good morning. On the staffing shortages again, you've been saying that you haven't seen them and I think you gave a number on how many psychiatrists you recruited, but your peer -- the pure-play peer and also the acute guys are talking about it. There's broad commentary in the country about mental health professionals being in short supply. Is there likely to be any wage pressure? There is a little bit of a pickup sequentially in your salaries line. And as you're recruiting, are you having to see any wage pressure on that that might be a bit of an offset?
是的,嗨,謝謝讓我提問。早安。再回到人力短缺的問題,你們一直說沒有看到短缺,我想你們也提到招募了多少精神科醫師,但你們的同業——純行為健康同業以及急性照護業者——都在談這件事。全國也普遍評論心理健康專業人員供給短缺。是否可能出現薪資壓力?你們的薪資項目確實有一些季比上升。那在招募時,你們是否也必須承受一些薪資壓力,可能會形成某種抵銷?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
We have, in our budget, a 2% to 3% merit increase of our employees next year and we think they're going to be able to attract the personnel to their facilities that they need to make sure we have the appropriate staffing in our facilities.
我們在預算中已納入明年員工 2% 到 3% 的績效調薪,我們認為他們將能吸引其機構所需的人員,以確保我們的機構有適當的人力配置。
So as I mentioned earlier, there are some isolated markets where we would -- we could have a shortage of a mental health tech or social workers or something like that, but there is nothing companywide. And then the reason we gave the physician numbers were -- gave you the physician numbers were, we gave you those numbers because we're doing well. The recruitment team is doing an outstanding job in finding physicians for our facilities.
如我先前提到的,確實有一些零星市場,我們可能會短缺心理健康技術員或社工之類的人力,但並非全公司層面的問題。至於我們提供醫師招募數字——之所以給你那些數字,是因為我們做得很好。招募團隊在為我們的機構尋找醫師方面表現非常出色。
So we've been able to work through that. This is the only thing we do is behavioral health. And those are the companies that you mentioned, they're also focused on med/surg operations too. So we've been able to find the employees for our facilities.
所以我們一直能夠克服這些問題。我們唯一做的就是行為健康。你提到的那些公司,他們也同時聚焦在內外科(med/surg)營運。因此,我們一直能為我們的機構找到所需員工。
Ana Gupte - Analyst
Ana Gupte - Analyst
So in the third quarter, the pick-up that you saw in your salaries line, is that --
所以第三季你們薪資項目看到的上升,是不是——
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Sure.
當然。
Ana Gupte - Analyst
Ana Gupte - Analyst
-- just kind of a -- in the third quarter of this -- yes.
——只是有點像——在今年第三季——是的。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It was primarily us coming in a little light on the revenue which makes that line a little bit bigger.
主要是因為我們營收略低於預期,讓那個項目看起來稍微大一些。
Ana Gupte - Analyst
Ana Gupte - Analyst
Okay.
好的。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
And our de novos, as they're wrapping up, with a higher level of salary and wages as a percent of net revenue. Those were the two reasons, Ana.
另外,我們的新設院(de novos)在收尾階段,薪資與工資占淨營收的比例較高。Ana,主要就是這兩個原因。
Ana Gupte - Analyst
Ana Gupte - Analyst
Okay. All right. Got it. And back to the IMD exclusion, I think so you say -- you've been saying you're expecting to recover your same-store growth. So I mean, I'm understanding that for next year between that inflexion point where you saw better volumes of patients days in October, you get back to that 7.5%-ish percent range? On the IMD side, is there an upside to that number or are you kind of looking at that as an offset to any pressure that you've seen so far when we think about recovery?
好的。好,了解。再回到 IMD 排除條款,我想你們說——你們一直說預期會恢復同店成長。所以我的理解是,明年在你們看到 10 月病患日數量改善的那個拐點之後,你們會回到大約 7.5% 左右的區間?在 IMD 方面,這個數字是否還有上行空間?還是你們把它視為對目前我們在復甦過程中看到的任何壓力的一種抵銷?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes. I think, again, taking it in perspective, the third quarter of 2016 and the third quarter of 2015 were the only two quarters we've seen sort of the mid-single-digit growth rate, which is in the 6% range, 6% to 6.5% for this year in the US. So kind of perspective-wise, I think everybody, you've to -- the growth rates that the company has done are unbelievable and it is not just pre-determined, right. I mean there is a lot of activity in our markets where people are taking care of very ill patients.
是的。我想,再次把它放在脈絡中看,2016 年第三季與 2015 年第三季是我們僅有的兩個季度,看到大約中個位數的成長率,也就是今年在美國約 6% 的區間,約 6% 到 6.5%。所以從角度來看,我想大家必須——公司過去做到的成長率非常驚人,而且這不是預先注定的,對吧。我的意思是,我們的市場有很多活動,人們正在照護病情非常嚴重的病患。
And so, I think you can look at it either way, but it's blended in there, the IMD effect in 2017 should certainly be positive for our volume initiatives. We're not going to say the guidance is going to be double digit because of that, coming off of a softer than expected quarter, but it certainly should be supportive of our outlook for continuing higher single-digit growth rates.
因此,我想你可以從兩個角度看,但 2017 年的 IMD 效應應該會對我們的量能推動措施帶來正面支持。我們不會因為這點、在一個比預期更疲弱的季度之後,就說指引會是雙位數成長,但它確實應該支持我們對持續高個位數成長率的展望。
Ana Gupte - Analyst
Ana Gupte - Analyst
And on the IMD, is this directly contracting with managed Medicaid when the states are ready or are you also doing this outsourcing kind of deals with acute facilities that don't want to deal with that population?
那在 IMD 方面,這是當各州準備好時,直接與管理式 Medicaid 簽約嗎?還是你們也在做那種與不想處理該族群的急性照護機構之間的外包交易?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
The IMD payer is managed Medicaid group, so there is -- that's our customer in the markets where we have managed Medicaid and now the ability to take the adults in those -- through those payers.
IMD 的付款方是管理式 Medicaid 團體,所以——在我們有管理式 Medicaid 的市場,那就是我們的客戶;而現在也能透過這些付款方,在那些市場收治成人。
Ana Gupte - Analyst
Ana Gupte - Analyst
So you're not talking about doing this acute JVs that [indiscernible]?
所以你不是在談做這種急性照護的合資(JV),像是[聽不清]那種?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Again, we have double-digit activity in our joint venture arrangements with not for profit health systems. They have been -- that activity has begun way before the IMD effect. We don't see just the IMD being a motivation for the partnership opportunities that we see going forward, but we have a lot of activity with joint venture partners for providing in-patient behavioral health in their markets.
再說一次,我們與非營利醫療體系的合資安排活動是雙位數成長。那樣的活動在 IMD 效應之前就已開始。我們不認為僅僅 IMD 會成為我們未來看到的合作機會的動機,但我們確實與合資夥伴有很多活動,在其市場提供住院型行為健康服務。
Ana Gupte - Analyst
Ana Gupte - Analyst
Got it. Okay. Then, one final question on the capital deployment back to the US. There was a very large [indiscernible] that was in play this year, and is that -- is that now completely off the table or might that come back on as an opportunity for you for next year perhaps?
了解。好。最後一個問題,關於把資本部署回美國。今年有一筆非常大的[聽不清]交易在進行中,那——那現在是否已完全不在考量範圍內?還是明年可能會再回來,成為你們的機會?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Are you asking about the bigger transaction, Ana?
Ana,你是在問那筆較大的交易嗎?
Ana Gupte - Analyst
Ana Gupte - Analyst
Yes, yes. [Indiscernible].
是的,是的。[聽不清]。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Well, there's -- Ana, this is Joey. There is three to five of those transactions that we could do any one of those that would be large enough that we would use the $360 million on.
嗯——Ana,我是 Joey。大概有三到五筆那種交易,我們任何一筆都可能做,而且規模都大到足以讓我們動用那 3.6 億美元。
Ana Gupte - Analyst
Ana Gupte - Analyst
Okay. So there is more opportunity than, okay, than that.
好的。所以機會比——好——比那一筆還多。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Yes.
是的。
Ana Gupte - Analyst
Ana Gupte - Analyst
All right. Thank you. Appreciate it.
好。謝謝。感謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Thank you.
謝謝。
Operator
Operator
And our next question comes from Paula Torch with Avondale Partners.
下一個問題來自 Avondale Partners 的 Paula Torch。
Paula Torch - Analyst
Paula Torch - Analyst
Great. Thanks for squeezing me in. Just quickly on those three to five transactions, Joey, are those sort of all in the acute or mental health space or is there maybe combination or maybe are they substance abuse? Just trying to get an idea of where we would be growing next year perhaps with the transactions you're looking at?
太好了。謝謝你把我塞進來。就快速問一下那三到五筆交易,Joey,那些大致上都是在急性照護或心理健康領域嗎?還是可能是組合,或是物質濫用相關?只是想了解一下,依你們正在看的交易,明年我們可能會在哪些領域成長。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
They would be more heavily weighted to the acute. There might be one transaction that has 90% acute and 10% addictive services, but primarily acute transactions.
會比較偏重在急性照護。可能會有一筆交易是 90% 急性照護、10% 成癮服務,但主要還是急性照護的交易。
Paula Torch - Analyst
Paula Torch - Analyst
Okay, great. Thanks. And in terms of just some of the weakness that we spoke about in the US, I think what you said in your comments that it was a little bit broad in a handful of facilities that you discussed -- so wondering were trends softer in these markets in the second quarter as well? And maybe is there anything regional that's going on, or is this something that is new in the third quarter and maybe came as somewhat of a surprise?
好的,很好,謝謝。那就我們剛才談到美國那邊的一些疲弱來看,我記得你在評論裡提到,這在你們討論的少數幾家機構中算是比較普遍——所以想請教,這些市場在第二季的趨勢也比較疲軟嗎?另外,是否有任何區域性的因素在發生,還是說這是第三季才出現、而且多少有點出乎意料?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It is not regional and it did come somewhat as a surprise. In the third quarter, you've got two major holidays, the July 4 and you've got Labor Day and you've got schools out. So obviously we have a large population of child and adolescents. So we're looking at all of those things. And coming off all the holidays, I know, Ron Fincher, our Chief Operating Officer, we're all anxious to see how the census ramps up after our major holiday and we had two of those in the quarter. And quite frankly, the numbers that we have for the third quarter are better than they were the year before for the third quarter and they're still strong numbers when you look at everybody else, so just a little soft.
這不是區域性的,而且確實多少有點出乎意料。第三季有兩個主要假期:7 月 4 日,還有勞動節,而且學校放假。所以很明顯,我們有很大一部分是兒童與青少年族群。我們會把這些因素都納入考量。每次假期過後,我知道我們的營運長 Ron Fincher,我們大家都很想看看在主要假期之後住院人數(census)會怎麼回升,而這一季我們有兩個假期。坦白說,我們第三季的數字比去年第三季還要好,而且跟其他人相比仍然是很強的數字,只是稍微偏軟一點。
Paula Torch - Analyst
Paula Torch - Analyst
Got it. Thank you.
了解,謝謝你。
Operator
Operator
Once again, we will hear from John Ransom with Raymond James.
接下來我們再次請 Raymond James 的 John Ransom 發問。
John Ransom - Analyst
John Ransom - Analyst
Hi. Thanks for taking the follow-up. Just going back to your comments on the M&A market that you've kind of lowered your asking price a little bit. Would you say there is a bid-ask spread between what you're now willing to pay and what bankers want to get? And also what's the difference between, say, a smaller deal and a larger deal in terms of kind of multiple expectations?
嗨,謝謝讓我追問。回到你對併購市場的評論,你們似乎把願意出的價格稍微下調了一點。你會說現在你們願意支付的價格,和投行想要拿到的價格之間存在買賣價差(bid-ask spread)嗎?另外,就倍數預期而言,小型交易和大型交易之間大概有什麼差異?
Brent Turner - President
Brent Turner - President
John, I would think the larger transactions are going to get around that nine times. A single transaction is probably going to get closer to the seven times. I think the bankers are beginning to realize that the multiples have come down and are coming down. And if they want to engage Acadia in the process that we've set those expectations that we're going to verify the trailing EBITDA earnings and that's the multiple we put to it. And if we lose the transaction, we lose the transaction, that's okay with us. We're going to do a good transaction, so that's where the market's at right now.
John,我認為大型交易大概會在 9 倍左右。單一(較小)的交易可能會更接近 7 倍。我覺得投行也開始意識到倍數已經下來、而且還在下來。如果他們想讓 Acadia 參與流程,我們已經設定好預期:我們會核實過去 12 個月(trailing)的 EBITDA 獲利,然後用那個倍數去套。如果我們失去那筆交易,就失去那筆交易,對我們來說沒關係。我們要做的是一筆好交易,所以目前市場大概就是這樣。
John Ransom - Analyst
John Ransom - Analyst
And this may be a little too in the weeds, but as you know, the SEC is tougher on pro forma EBITDA adjustments. So how do you handle trying to square the circle between, okay, here is the trailing EBITDA. But if you add back these 472 things in synergies and 2,058, here is the real EBITDA, what's your tolerance for actual versus pro forma, generally speaking?
這可能有點太細,但你也知道,SEC 對於備考(pro forma)EBITDA 的調整更嚴格了。所以你們怎麼處理這種矛盾:好,這是過去 12 個月的 EBITDA;但如果加回這 472 項協同效益、再加回 2,058 項,這才是真正的 EBITDA——一般來說,你們對「實際」與「備考」之間的容忍度是什麼?
David Duckworth - CFO
David Duckworth - CFO
John, this is David. We present just the adjusted EBITDA with very few adjustments. We like to back out only the items that are directly related to our acquisitions. So we've always had the transaction costs as we've been acquisitive, and then for this quarter, it's just the divestiture items. So we don't believe there's anything unusual from that perspective that we are adjusting.
John,我是 David。我們呈現的是調整後 EBITDA,而且調整項目非常少。我們只會剔除那些與我們收購直接相關的項目。所以我們一向會有交易成本,因為我們一直在做收購;而本季則只有處分(divestiture)相關項目。因此我們不認為在我們所做的調整方面有任何不尋常之處。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
And we would want to keep them, John --
而且我們會希望把它們保留,John——
John Ransom - Analyst
John Ransom - Analyst
Sorry.
抱歉。
David Duckworth - CFO
David Duckworth - CFO
He is asking, not how we report them, but how the seller presents them.
他問的不是我們怎麼報告,而是賣方怎麼呈現。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Oh! Seller.
喔!賣方。
John Ransom - Analyst
John Ransom - Analyst
How do you go back and forth with sellers who want to get all kind of credit for pro forma adjustments? Which ones are you willing to give credit for and which ones are you not in general?
你們如何和賣方來回協商?賣方想把各種備考調整都算進去、拿到相應的價值。一般來說,哪些調整你們願意給予認列,哪些不願意?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
We're not going to pay for two beds two years out. And about the only thing we'll pay for is if it's the single owner and they're taking out management fees or an unusual salary, they might get credit for that.
我們不會為兩年後的兩張床位付錢。我們大概唯一會付的,是如果是單一業主,他們把管理費拿掉,或是有不尋常的薪資,他們可能可以因此獲得一些認列。
John Ransom - Analyst
John Ransom - Analyst
Okay. And are you generally -- is the big, in other areas of healthcare, the big good guy is better managed care rates over time. Did you find that to be the case, if that's an opportunity for you? Or what's the, let's say you want to drive that multiple from nine times to seven times, is it new beds that you're going to build? Or is it managed care rates? Is it staffing? Or is it none of those or all of those?
好的。那一般來說——在醫療保健的其他領域,最大的利多往往是隨時間推進更好的商業保險(managed care)費率。你們是否也看到這種情況、也就是對你們而言是一個機會?或者說,假設你想把倍數從 9 倍壓到 7 倍,主要靠的是你要新建床位?還是靠商業保險費率?還是人力配置?或是都不是、或是全部都有?
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
It's 90% of it is going to be a new program that they don't have, a new service line or beds that they need to be built. Prime example is Murfreesboro, the facility we bought there. They were turning away hundreds of patients a quarter, but the venture capital company did not have the capital to do the next 80-bed expansion. So that is the most recent example.
其中 90% 會是他們沒有的新方案、新的服務線,或是需要新建的床位。最典型的例子是我們在 Murfreesboro 買的那家機構。他們每季都要拒收數百名病患,但那家創投公司沒有資本去做下一階段的 80 床擴建。所以這是最近的例子。
John Ransom - Analyst
John Ransom - Analyst
All right. Thanks a lot.
好,謝謝。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Thanks, John. Go vote.
謝謝你,John。去投票吧。
Operator
Operator
And with no further questions in the queue, I'd like to turn the call back over to Mr. Jacobs for closing remarks.
由於佇列中沒有其他問題,我想把電話交回給 Jacobs 先生做結語。
Joey Jacobs - Chairman, CEO
Joey Jacobs - Chairman, CEO
Once again, thanks everyone for your interest in Acadia. Future looks bright for us. We have a lot of hard work ahead for us, lot of execution for the facilities I've been out and visited with during the quarter. Thank you for your hospitality for the teams out there in the de novos. We know you have an extra hard job of ramping up your facilities and we very much appreciate all the work you're doing there. So once again, we'll see you at the end of our next quarter.
再次感謝各位對 Acadia 的關注。我們的未來看起來很光明。我們前面還有很多艱鉅的工作要做,也需要大量的執行力;本季我外出拜訪過的那些機構就是如此。也謝謝在 de novos(新設機構)現場團隊對我們的熱情款待。我們知道你們在把機構規模拉升(ramp up)方面有一份格外辛苦的工作,我們非常感謝你們在那裡所做的一切。那麼再次感謝,我們下個季度結束時再見。
Operator
Operator
That concludes today's conference. Thank you for your participation. You may now disconnect.
今天的電話會議到此結束。感謝各位的參與。您現在可以掛線。